Patient Voices Take Center Stage as Bronchiectasis Community Plans Landmark FDA Drug Development Meeting

The Bronchiectasis and NTM Association, a nonprofit organization dedicated to improving the lives of people affected by bronchiectasis and nontuberculous mycobacterial lung disease, has announced plans for an Externally-Led Patient-Focused Drug Development meeting dedicated to non-cystic fibrosis bronchiectasis, a chronic and often debilitating lung condition that has historically struggled to attract sustained attention from the pharmaceutical industry. The announcement, made from Miami on October 14, 2026, signals a deliberate effort to place the lived experiences of patients at the very center of how new therapies are conceived, evaluated, and ultimately approved. The meeting is modeled directly on the Food and Drug Administration’s own Patient-Focused Drug Development public meetings, a format the agency has used for years to gather systematic, patient-generated evidence about the symptoms, burdens, and treatment priorities that matter most to people living with specific diseases.

Externally-led meetings of this kind occupy a distinctive position in the regulatory landscape. While the FDA convenes its own patient-focused meetings for selected conditions, patient organizations can also host externally-led versions that follow the same structured approach, inviting patients, caregivers, clinicians, drug developers, and regulators to a common forum. In this case, the Association has confirmed that drug developers, the FDA, and other stakeholders will be in attendance, meaning that the testimony gathered during the proceedings will reach precisely the audiences capable of acting on it. The goal is not simply to document suffering but to convert personal narratives into structured evidence that can inform clinical trial design, endpoint selection, benefit-risk assessment, and regulatory decision-making for years to come.

Non-cystic fibrosis bronchiectasis is a chronic lung disease characterized by persistent inflammation and chronic infection, in which the airways become abnormally widened, thickened, or scarred. This structural damage impairs the lungs’ ability to clear mucus, creating a vicious cycle in which retained secretions harbor bacteria, bacterial colonization drives further inflammation, and ongoing inflammation deepens the airway injury. Patients typically experience chronic cough, copious sputum production, recurrent respiratory infections, breathlessness, and profound fatigue. Exacerbations, the acute worsening episodes that punctuate the disease’s course, can force hospitalization and are associated with accelerated loss of lung function over time. The daily burden of managing airway clearance, antibiotics, and the psychological weight of a lifelong condition is substantial and often invisible to those outside the patient community.

For decades, the disease was considered rare, a classification that shaped nearly every aspect of the research and treatment environment surrounding it. Rare disease status typically means small patient populations, fragmented clinical data, limited commercial incentives for drug development, and lengthy diagnostic delays. As the Association notes, however, the picture has changed considerably in recent years. Growing awareness, expanded research activity, and advances in imaging, particularly high-resolution computed tomography, have dramatically improved the ability of clinicians to recognize and characterize the disease. Epidemiological studies across multiple countries have suggested that bronchiectasis is more common than previously appreciated, particularly among older adults, and the condition is now recognized more widely throughout the medical community. This shift in recognition has laid the groundwork for the therapeutic progress now beginning to emerge.

That progress reached a watershed moment in 2025, when the first FDA-approved treatment for non-cystic fibrosis bronchiectasis became available. The approval ended a long era in which patients and their physicians had to rely entirely on off-label approaches, borrowed from cystic fibrosis care or general respiratory medicine, to manage a disease with its own distinct biology. Yet the Association is careful to frame this milestone as a beginning rather than an endpoint. Many people with the condition still face delays in diagnosis, limited access to specialized care, and persistent difficulties managing the disease’s daily impact. A single approved therapy, however significant, cannot address the full spectrum of patient needs, and the Association’s announcement makes clear that significant unmet needs remain across the community.

The planned meeting has been structured around three explicit objectives. First, it aims to enhance understanding of how living with non-cystic fibrosis bronchiectasis impacts daily life experiences, capturing dimensions of the disease that conventional clinical measures often miss. Second, it seeks to capture diverse perspectives from across the NCFB community in order to foster timely and effective therapy development, ensuring that the pipeline reflects the heterogeneity of the patient population rather than a narrow slice of it. Third, it intends to inform regulatory decision-making with insights on current care and treatment benefit needs, giving reviewers and policymakers a grounded picture of what patients would consider meaningful improvement. Together, these objectives reflect a maturing philosophy in drug development: that patient input is not anecdote but data.

Elisha Malanga, Executive Director of the Bronchiectasis and NTM Association, emphasized the significance of the moment in a statement accompanying the announcement. The first FDA-approved treatment for the disease marked an important milestone, she said, but significant unmet needs remain, and the daily burden of the disease continues to affect many people living with the condition. She described the initiative as an important opportunity to ensure that the voices of people living with non-cystic fibrosis bronchiectasis are heard by the FDA, researchers, and treatment developers, and she noted that by sharing their experiences, challenges, and priorities, community members can help shape a deeper understanding of the disease and inform the development of future treatments that address what matters most to them.

The meeting itself is proposed for late 2027, a timeline that gives the Association and its partners ample opportunity to prepare. Crucially, the event will include a virtual element, a design choice intended to ensure accessibility for all attendees regardless of geography, health status, or mobility. This consideration matters enormously for a lung disease community in which many patients manage chronic infection and fatigue that can make travel difficult or risky. The Association has committed to engaging a wide array of NCFB community stakeholders in support of the initiative, and additional information about the meeting, including details on participation, will be released at a later date. The extended runway also allows time for structured pre-meeting surveys and outreach, tools commonly used in patient-focused drug development to reach patients who cannot attend live sessions.

The broader significance of the announcement extends beyond a single disease community. Patient-focused drug development has become one of the most consequential shifts in modern regulatory science, reflecting a growing consensus that clinical trial endpoints must align with outcomes patients actually value. For a condition like non-cystic fibrosis bronchiectasis, where exacerbation frequency, symptom burden, and quality of life are central to the patient experience, systematically collected patient input can help sponsors design trials that measure what matters, potentially shortening development timelines and improving the odds that approved therapies deliver tangible benefit. It can also help regulators weigh benefits and risks in ways that reflect real-world priorities rather than surrogate measures alone.

For the bronchiectasis and NTM community, the announcement represents both recognition and momentum. An organization founded to serve patients with two closely related and long-neglected conditions is now convening the full machinery of drug development, from regulators to industry, around the testimony of the people who live with the disease every day. If the meeting fulfills its stated aims, the experiences shared in late 2027 could echo through trial protocols, regulatory reviews, and ultimately treatment options for a patient population that has waited far longer than most for therapies designed specifically for them. Additional details about the meeting will be announced by the Association as planning progresses.

Subject of Research: An externally-led patient-focused drug development meeting for non-cystic fibrosis bronchiectasis announced by the Bronchiectasis and NTM Association.

Article Title: Bronchiectasis and NTM Association announces Externally-Led Patient-Focused Drug Development meeting for non-cystic fibrosis bronchiectasis

Article References: Bronchiectasis and NTM Association announces Externally-Led Patient-Focused Drug Development meeting for non-cystic fibrosis bronchiectasis. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: bronchiectasis, NTM, NCFB, PFDD, FDA, drug development, patient advocacy, lung disease, clinical research, regulatory decision-making, COPD Foundation, rare disease